ArticleFrontiers in neurology2025
Serum P2X7 as a prognostic biomarker in acute supratentorial intracerebral hemorrhage: a two-center observational study.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: P2X7 participates in neuroinflammation underlying acute brain injury. In this study, we investigated the prognostic role of serum P2X7 in acute intracerebral hemorrhage (ICH). Methods: This two-center observational analytic study enrolled 95 controls and 196 patients with acute supratentorial ICH. Serum P2X7 levels were measured at study entry in controls and at admission in all ICH patients, with serial measurements performed in a subgroup of 95 patients. Disease severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) and hematoma volume. The primary neurological functional outcome was assessed using the modified Rankin Scale (mRS) at 6 months post-ICH. Multivariable analysis was performed to model the associations between P2X7 levels, disease severity, and final functional prognosis. Results: In patients with ICH, serum P2X7 levels were markedly elevated upon admission, peaked at day 3, and gradually declined through to day 10. Patient serum P2X7 levels remained notably higher than those of controls throughout the 10-day period. Serum P2X7 levels were linearly correlated with NIHSS scores, hematoma volume, mRS scores, and poor prognosis (mRS 3-6) under restricted cubic spline analysis. These associations persisted after adjustment for potential confounding factors. Sensitivity analyses, subgroup analyses, and receiver operating characteristic (ROC) curve analysis consistently demonstrated that serum P2X7 levels were robustly associated with poor prognosis. Applying calibration curve, decision curve, ROC curve, and model improvement rate analyses, a combined model integrating serum P2X7 levels, NIHSS scores, and hematoma volume demonstrated strong performance. Furthermore, serum P2X7 levels partially mediated the correlations of NIHSS scores and hematoma volume with poor prognosis. Discussion: Increased serum P2X7 levels after ICH are markedly associated with disease severity and poor prognosis. Moreover, P2X7 may partially mediate the relationship between ICH severity and prognosis, underscoring its potential as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.